Ipsen Employee Pleads Guilty to Insider Trading in Cancer Drug Acquisition Case

Dishant Gupta, an employee of French drugmaker Ipsen, has agreed to plead guilty to securities fraud. Gupta made over $262,000 through insider trading by leveraging information about Ipsen's acquisition of cancer drug developer Epizyme in 2022. He is set for a plea hearing on Oct. 8.

Dishant Gupta, an employee of French pharmaceutical giant Ipsen, has agreed to admit guilt in a case of insider trading, netting over $262,000 based on privileged information about Ipsen's 2022 plans to acquire cancer drug developer Epizyme.

Gupta, who served as Ipsen's director of data strategy and operations, is expected to plead guilty to securities fraud and will settle related charges with the U.S. Securities and Exchange Commission, as per court documents in Boston federal court.

The plea hearing is scheduled for Oct. 8. Gupta's lawyer, Jeffrey Lichtman, confirmed his client is cooperating to resolve the matter. Ipsen has refrained from commenting on ongoing legal issues concerning its employees, emphasizing its commitment to legal compliance.

(With inputs from agencies.)